The U.S. Centers for Disease Control and Prevention (CDC) has revised its guidance on COVID-19 vaccines for children, stating that vaccination for healthy individuals aged 6 months to 17 years should follow a “shared clinical decision-making” process. This means that shots are still available, but only if parents and doctors agree it's necessary based on individual circumstances.
The move marks a shift from earlier CDC guidance, which broadly recommended updated COVID-19 vaccines for everyone six months and older. The updated schedule, published Thursday, outlines that if parents want their child vaccinated, they may proceed based on a healthcare provider’s judgment and the family’s preference.
Health Secretary Robert F. Kennedy Jr., a known vaccine skeptic, claimed earlier in the week that COVID vaccines for healthy children and pregnant women had been removed from the CDC’s immunization schedule. However, a Department of Health and Human Services spokesperson said there is no contradiction, as the CDC’s updated guidance no longer promotes universal vaccination for healthy children but still allows it case-by-case.
Medical experts criticized Kennedy’s unilateral announcement, saying it bypassed the CDC’s usual advisory process. The Infectious Diseases Society of America warned the change may limit access and insurance coverage, especially for vulnerable children. They emphasized that COVID-19 can cause serious illness in children, including long COVID symptoms that may impact development.
According to CDC data, nearly 1,900 children under 18 have died from COVID-19 in the U.S. as of 2023. Vaccine makers Pfizer, Moderna, and Novavax have not commented on the development.
The FDA also recently announced it would require new clinical trials for annual COVID boosters in healthy individuals under 65, reinforcing a more limited use strategy moving forward.


Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change
Australia’s Under-16 Social Media Ban Sparks Global Debate and Early Challenges
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
DOJ Sues Loudoun County School Board Over Transgender Locker Room Policy
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Trump Taps Former DHS Official Troy Edgar for U.S. Ambassador Role in El Salvador
Trump Administration Fuel-Efficiency Rollback Could Raise Long-Term Costs for U.S. Drivers
Trump Set to Begin Final Interviews for Next Federal Reserve Chair
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
EU Expands Carbon Border Levy to Car Parts and Appliances, Tightening Climate Trade Rules
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Australia Pushes Forward on AUKUS Submarine Program Amid Workforce and Production Challenges 



